Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/05/293   
Active ingredient: nelarabine
Indication: Treatment of acute lymphoblastic leukaemia
Sponsor: Glaxo Group Ltd
980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Atriance on 22/08/2007 with the number EU/1/07/403

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
20/06/2005 Orphan Designation EMEA/OD/013/05 (2005)1881 of 16/06/2005
23/08/2006 Transfer of orphan designation EMEA/OD/013/05/T/01 (2006)3838 of 21/08/2006
04/02/2014 Change of address of sponsor